Zydus Lifesciences Limited (NSE:ZYDUSLIFE)
989.80
+1.90 (0.19%)
Oct 8, 2025, 12:31 PM IST
Zydus Lifesciences Revenue
Zydus Lifesciences had revenue of 65.74B INR in the quarter ending June 30, 2025, with 5.90% growth. This brings the company's revenue in the last twelve months to 236.08B, up 14.52% year-over-year. In the fiscal year ending March 31, 2025, Zydus Lifesciences had annual revenue of 232.42B with 18.90% growth.
Revenue (ttm)
236.08B
Revenue Growth
+14.52%
P/S Ratio
4.21
Revenue / Employee
8.46M
Employees
27,917
Market Cap
994.06B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 232.42B | 36.94B | 18.90% |
Mar 31, 2024 | 195.47B | 23.10B | 13.40% |
Mar 31, 2023 | 172.37B | 21.28B | 14.08% |
Mar 31, 2022 | 151.10B | 7.06B | 4.90% |
Mar 31, 2021 | 144.04B | 1.50B | 1.06% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 537.77B |
Divi's Laboratories | 96.52B |
Cipla | 274.80B |
Apollo Hospitals Enterprise | 225.51B |
Mankind Pharma | 129.10B |
Fortis Healthcare | 80.94B |
Alkem Laboratories | 133.04B |
Aurobindo Pharma | 320.25B |
Zydus Lifesciences News
- 1 day ago - Zydus Lifesciences receives Health Canada approval for Liothyronine tablets 5 mcg and 25 mcg - Business Upturn
- 1 day ago - Zydus Lifesciences gets USFDA nod for Deflazacort oral suspension - Business Upturn
- 7 days ago - Zydus Lifesciences extends closing date for acquisition of Sterling Biotech’s API business - Business Upturn
- 12 days ago - Trump’s 100% tariffs on pharma: Sun Pharma, Biocon, Cipla & other pharmaceutical stocks tank; jitters on D-Street - The Times of India
- 12 days ago - Zydus Lifesciences shares slip nearly 3% as Trump’s pharma tariff rattles sector - Business Upturn
- 22 days ago - Zydus Lifesciences’ ZyVet launches first veterinary-approved generic of Furosemide tablets - Business Upturn
- 22 days ago - Zydus Lifesciences’ ZyVet launches first FDA-approved generic treatment for canine urinary incontinence - Business Upturn
- 27 days ago - Basal Cell Neoplasms Clinical Trial Pipeline Accelerates as 22+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Benzinga